Which carbonic anhydrase inhibitor is more commonly used for chronic therapy?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Boost your readiness for the Primary Open-Angle Glaucoma Test. Utilize flashcards and multiple-choice questions complete with hints and detailed explanations to enhance your understanding.

Multiple Choice

Which carbonic anhydrase inhibitor is more commonly used for chronic therapy?

Explanation:
The concept here is choosing a carbonic anhydrase inhibitor for long-term management of glaucoma. Methazolamide is favored for chronic oral therapy because it provides effective IOP reduction with better tolerability and a longer-lasting effect than acetazolamide. It tends to cause fewer systemic side effects like metabolic acidosis, renal bicarbonate loss, and diuretic effects, which makes it more suitable for ongoing use. While topical carbonic anhydrase inhibitors (eye drops) are also used long-term, the traditional choice for a chronic systemic regimen is methazolamide due to its balance of efficacy and tolerability over time.

The concept here is choosing a carbonic anhydrase inhibitor for long-term management of glaucoma. Methazolamide is favored for chronic oral therapy because it provides effective IOP reduction with better tolerability and a longer-lasting effect than acetazolamide. It tends to cause fewer systemic side effects like metabolic acidosis, renal bicarbonate loss, and diuretic effects, which makes it more suitable for ongoing use. While topical carbonic anhydrase inhibitors (eye drops) are also used long-term, the traditional choice for a chronic systemic regimen is methazolamide due to its balance of efficacy and tolerability over time.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy